Author/Authors :
Sheikholeslami, Sara Cellular and Molecular Endocrine Research Center - Research Institute for Endocrine Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Azizi, Fereidoun Endocrine Research Center - Research Institute for Endocrine Sciences - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ghasemi, Asghar Endocrine Physiology Research Center - Research Institute for Endocrine Sciences - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Alibakhshi, Abbas Department of General Surgery - Imam Khomeini Hospital Complex - Tehran University of Medical Sciences, Tehran, Iran , Parsa, Hossein Department of Surgery - Velayat Hospital - Qazvin University of Medical Sciences, Qazvin, Iran , Tavangar, Mohammad Department of Pathology - Dr. Shariati Hospital - Tehran University of Medical Sciences, Tehran, Iran , Shivaee, Setareh Cellular and Molecular Endocrine Research Center - Research Institute for Endocrine Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Zarif Yeganeh, Marjan Cellular and Molecular Endocrine Research Center - Research Institute for Endocrine Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Hedayati, Mehdi Cellular and Molecular Endocrine Research Center - Research Institute for Endocrine Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Teimoori-Toolabi, Ladan Molecular Medicine Department - Biotechnology Research Center - Pasteur Institute of Iran, Tehran, Iran
Abstract :
Background: Thyroid cancer is the fourth most common cancer in the world. Papillary thyroid carcinoma (PTC) accounts for 80%
of all types of thyroid neoplasm. Epigenetic alterations such as DNA methylation are known as the main cause of different types of
cancers through inactivation of tumor suppressor genes.
Objectives: In the present study, the expression and methylation of suggested gene namely nucleolar protein 4 (NOL4) in PTC in
comparison to multi nodular goiter (MNG) have been studied.
Methods: Forty-one patients with PTC and 38 patients affected by MNG were recruited. Thyroid tissues were obtained during thyroidectomy.
RNAandDNAwere extracted from thyroid tissues. Quantitative RT-PCR assay was performed for determining themRNA
level of NOL4 while methylation-sensitive high resolution methylation was applied for assessing the methylation status with designing
six pairs primers for six regions on gene promoter which were named from NOL4 (a) to NOL4 (f).
Results: Methylation assessment of 81 CpG islands in the promoter region of NOL4 gene revealed that NOL4 (f), the nearest region
to the start codon, was significantly hypermethylated in PTC cases compared to MNG cases. NOL4 level in PTC cases in comparison
withMNGcases were downregulated. The methylation status andmRNAlevel of NOL4 (f) were associated with age of diagnosis (Age
of the patient at the time of diagnosis), lymph node metastasis, and advanced stages of disease.
Conclusions: These data suggested an aberrant promoter hyper-methylation of NOL4 in PTC cases may be linked with its downregulation.
Therefore, NOL4 gene can be proposed as a potential tumor suppressor gene in PTC tissues.
Keywords :
Papillary , Thyroid Cancer , NOL4 , Tumor Suppressor , Genes , Gene Expression , DNA Methylation